WHO Reviews Malaria Vaccine Pipeline with Two Prequalified

In June 2026, the World Health Organization (WHO) conducted a comprehensive review of the malaria vaccine pipeline, focusing on candidates in clinical development as of December 2025. This review identified a total of 147 vaccine candidates, with two—RTS,S/AS01E and R21/Matrix-M—prequalified and recommended by WHO. It emphasized significant progress in vaccine development, particularly in the fight against malaria, a disease that continues to challenge public health in many parts of the world.

The historical context of malaria vaccine development has evolved considerably over the years, driven by the urgent need to combat malaria caused by the Plasmodium parasite. The WHO review categorized vaccines based on their clinical development phases, ranging from phase I to phase IV. By the end of 2025, the review noted that 43 candidates were actively undergoing trials, with a notable 65% in phase I and 33% in phase II. This reflects a strong interest and investment in malaria vaccine research, aiming to provide effective solutions against the disease.

The implementation of these vaccine trials involves diverse stakeholders, including research institutions, pharmaceutical companies, and public health organizations. Conducted across various countries, these trials allow researchers to gather data on vaccine efficacy and safety among different populations. The active candidates primarily target Plasmodium falciparum, which accounts for the majority of malaria cases, as well as Plasmodium vivax. Collaborative efforts among these stakeholders are crucial for advancing the development of effective malaria vaccines.

The broader economic, environmental, and social benefits of malaria vaccine development are significant. Successful vaccines can greatly reduce the incidence of malaria, leading to improved public health outcomes, lower healthcare costs, and enhanced productivity in affected regions. Furthermore, these vaccines contribute to the global goal of eradicating malaria, aligning with various sustainable development objectives. The focus on malaria vaccine development also fosters research and innovation within the broader field of infectious diseases.

Looking ahead, the future for malaria vaccine development appears promising, with ongoing trials and research efforts expected to yield more candidates. The WHO's endorsement of RTS,S/AS01E and R21/Matrix-M marks a significant milestone, encouraging further investment and collaboration in this area. The global significance of these developments is profound, representing a collective effort to combat a disease that has plagued humanity for centuries and continues to affect millions worldwide.